Results 221 to 230 of about 76,287 (256)
Some of the next articles are maybe not open access.
Glucagon-Like Peptide 1—A Cardiologic Dimension
Trends in Cardiovascular Medicine, 2010Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant.
Treiman, Marek +3 more
openaire +3 more sources
Glucagon-like peptide-1 receptor
Current BiologyMichael Krashes discusses glucagon-like peptide-1 receptors, their physiological role in glucose metabolism and the mode of action of their agonists that are used to treat obesity and were later shown to promote weight loss.
openaire +2 more sources
Microcirculation, 2019
AbstractGLP‐1 and GLP‐2 are gut‐derived hormones used in the treatment of diabetes type‐2 and short bowel syndrome, respectively. GLP‐1 attenuates insulin resistance and GLP‐2 reduces enterocyte apoptosis and enhances crypt cell proliferation in the small intestine. In addition, both hormones have vasoactive effects and may be useful in situations with
Nikolaj Nerup +5 more
openaire +3 more sources
AbstractGLP‐1 and GLP‐2 are gut‐derived hormones used in the treatment of diabetes type‐2 and short bowel syndrome, respectively. GLP‐1 attenuates insulin resistance and GLP‐2 reduces enterocyte apoptosis and enhances crypt cell proliferation in the small intestine. In addition, both hormones have vasoactive effects and may be useful in situations with
Nikolaj Nerup +5 more
openaire +3 more sources
Glucagon-like peptide-1 medicines and cancer
Nature CancerGlucagon-like peptide-1 (GLP-1) medicines reduce food intake, body weight, insulin resistance and inflammation, thus improving outcomes for people with type 2 diabetes and obesity and potentially contributing to decreased cancer incidence. GLP-1 medicines acting through weight loss-dependent and weight loss-independent mechanisms hold potential for ...
Julian M. Yabut, Daniel J. Drucker
openaire +2 more sources
Glucagon-Like Peptide 1 and the Cardiovascular System
Current Diabetes Reviews, 2014Glucagon-like peptide 1 (GLP1) is a major incretin hormone. This means that it is secreted by the gut in response to food and helps in reducing post-prandial glucose exertion. It achieves this through a number of mechanisms, including stimulating insulin release by pancreatic β-cells in a glucose-dependent manner; inhibition of glucagon release by ...
openaire +2 more sources
Glucagon and Glucagon-Like Peptides 1 and 2
2009The glucagon gene is expressed not only in the alpha cells of the pancreatic islets but also in the endocrine cells of the intestinal epithelium (so-called L-cells), and in certain neurons of the brain stem. Whereas in the pancreas, glucagon, the hyperglycaemic hormone, is cleaved out of the 160 amino acid precursor, proglucagon, leaving behind ...
openaire +3 more sources
Glucagon-like peptide-1, a new hormone of the entero-insular axis
Diabetologia, 1992Ørskov C, C Ørskov
exaly